The HEARTS partner forum-supporting implementation of HEARTS to treat and control hypertension.
cardiovascular diseases
global health
health systems
hypertension
implementation
partnerships
primary healthcare
universal health coverage
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
03
2023
accepted:
03
07
2023
medline:
10
8
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
epublish
Résumé
Cardiovascular diseases (CVD), principally ischemic heart disease (IHD) and stroke, are the leading causes of death (18. 6 million deaths annually) and disability (393 million disability-adjusted life-years lost annually), worldwide. High blood pressure is the most important preventable risk factor for CVD and deaths, worldwide (10.8 million deaths annually). In 2016, the World Health Organization (WHO) and the United States Centers for Disease Control (CDC) launched the Global Hearts initiative to support governments in their quest to prevent and control CVD. HEARTS is the core technical package of the initiative and takes a public health approach to treating hypertension and other CVD risk factors at the primary health care level. The HEARTS Partner Forum, led by WHO, brings together the following 11 partner organizations: American Heart Association (AHA), Center for Chronic Disease Control (CCDC), International Society of Hypertension (ISH), International Society of Nephrology (ISN), Pan American Health Organization (PAHO), Resolve to Save Lives (RTSL), US CDC, World Hypertension League (WHL), World Heart Federation (WHF) and World Stroke Organization (WSO). The partners support countries in their implementation of the HEARTS technical package in various ways, including providing technical expertise, catalytic funding, capacity building and evidence generation and dissemination. HEARTS has demonstrated the feasibility and acceptability of a public health approach, with more than seven million people already on treatment for hypertension using a simple, algorithmic HEARTS approach. Additionally, HEARTS has demonstrated the feasibility of using hypertension as a pathfinder to universal health coverage and should be a key intervention of all basic benefit packages. The partner forum continues to find ways to expand support and reinvigorate enthusiasm and attention on preventing CVD. Proposed future HEARTS Partner Forum activities are related to more concrete information sharing between partners and among countries, expanded areas of partner synergy, support for implementation, capacity building, and advocacy with country ministries of health, professional societies, academy and civil societies organizations. Advancing toward the shared goals of the HEARTS partners will require a more formal, structured approach to the forum and include goals, targets and published reports. In this way, the HEARTS Partner Forum will mirror successful global partnerships on communicable diseases and assist countries in reducing CVD mortality and achieving global sustainable development goals (SDGs).
Identifiants
pubmed: 37554732
doi: 10.3389/fpubh.2023.1146441
pmc: PMC10405076
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1146441Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Copyright © 2023 Khan, Moran, Perel, Whelton, Brainin, Feigin, Kostova, Richter, Ordunez, Hennis, Lackland, Slama, Pineiro, Martins, Williams, Hofstra, Garg and Mikkelsen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2021 Sep 11;398(10304):957-980
pubmed: 34450083
Rev Panam Salud Publica. 2022 Jul 16;46:e96
pubmed: 35855441
J Clin Hypertens (Greenwich). 2020 Oct;22(10):1769-1779
pubmed: 32815663
Hypertension. 2022 Jan;79(1):293-301
pubmed: 34775787
J Clin Hypertens (Greenwich). 2020 Feb;22(2):142-149
pubmed: 31967722
Lancet. 2020 Sep 26;396(10255):918-934
pubmed: 32891217
BMJ Open. 2022 Jun 27;12(6):e061467
pubmed: 35760540
Hypertension. 2021 Mar 3;77(3):806-812
pubmed: 33517681
BMJ Glob Health. 2020 Sep;5(9):
pubmed: 32912853
Rev Port Cardiol (Engl Ed). 2020 Jan;39(1):27-34
pubmed: 32143997
Rev Panam Salud Publica. 2022 Sep 02;46:e140
pubmed: 36071923
Nat Med. 2022 Aug;28(8):1693-1699
pubmed: 35851877
J Clin Hypertens (Greenwich). 2020 Aug;22(8):1296-1309
pubmed: 33289261
BMC Public Health. 2018 Jun 11;18(1):722
pubmed: 29890937
Can J Cardiol. 2021 May;37(5):744-755
pubmed: 33310142
Rev Panam Salud Publica. 2022 Sep 17;46:e165
pubmed: 36128471
J Hum Hypertens. 2023 Jul;37(7):560-567
pubmed: 35945426
Lancet Reg Health Am. 2022 May;9:None
pubmed: 35711684
Lancet. 2022 Mar 26;399(10331):1266-1278
pubmed: 35339227
Rev Panam Salud Publica. 2022 Sep 15;46:e144
pubmed: 36128473
J Clin Hypertens (Greenwich). 2021 Apr;23(4):755-765
pubmed: 33738969
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175